A non-hallucinogenic psychedelic analogue with therapeutic potential

Area of Science:

• Neuroscience
• Medicinal Chemistry
• Pharmacology

Background:

• The psychedelic alkaloid ibogaine exhibits anti-addictive properties, showing potential for treating substance use disorders.
• Ibogaine's long-lasting effects are linked to modifying neural circuitry via neurotrophic factor signaling.
• Clinical development of ibogaine is limited by safety concerns, including toxicity, hallucinogenic effects, and cardiac arrhythmias.

Purpose of the Study:

• To identify key structural elements of ibogaine's therapeutic pharmacophore using function-oriented synthesis.
• To engineer a safer, non-hallucinogenic, and water-soluble analogue of ibogaine with therapeutic potential.

Main Methods:

• Applied function-oriented synthesis to determine ibogaine's critical structural components for therapeutic action.
• Chemically engineered a novel analogue, tabernanthalog, based on identified structural elements.
• Evaluated tabernanthalog's effects on neural plasticity, substance-seeking behavior, and mood in rodent models.

Main Results:

• Tabernanthalog was successfully synthesized as a single-step, water-soluble, non-hallucinogenic, and non-toxic ibogaine analogue.
• In rodents, tabernanthalog promoted structural neural plasticity.
• Tabernanthalog significantly reduced alcohol- and heroin-seeking behaviors and demonstrated antidepressant-like effects.

Conclusions:

• Chemical modification of psychedelic compounds can yield safer, non-hallucinogenic variants with therapeutic potential.
• Tabernanthalog represents a promising candidate for developing novel treatments for addiction and related disorders.
• This study highlights the successful application of rational drug design in modifying psychoactive substances for therapeutic benefit.